• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GILD

    Gilead Sciences Inc.

    Subscribe to $GILD
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

    IPO Year: 1992

    Exchange: NASDAQ

    Website: gilead.com

    Peers

    $ABBV
    $BMY
    $MRK
    $PFE

    Recent Analyst Ratings for Gilead Sciences Inc.

    DatePrice TargetRatingAnalyst
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    2/18/2025$120.00Hold → Buy
    Deutsche Bank
    2/13/2025$108.00Hold → Buy
    DZ Bank
    1/10/2025$87.00 → $113.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$109.00Buy
    BofA Securities
    11/15/2024$110.00Outperform
    Wolfe Research
    11/14/2024$125.00Buy
    Citigroup
    11/8/2024Buy → Hold
    Maxim Group
    10/21/2024$74.00 → $96.00Market Perform → Outperform
    Leerink Partners
    See more ratings

    Gilead Sciences Inc. SEC Filings

    See more
    • Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/8/25 5:26:08 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Gilead Sciences Inc.

      10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/7/25 4:32:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      4/24/25 4:03:59 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Gilead Sciences Inc.

      DEFA14A - GILEAD SCIENCES, INC. (0000882095) (Filer)

      3/27/25 4:31:21 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Gilead Sciences Inc.

      DEF 14A - GILEAD SCIENCES, INC. (0000882095) (Filer)

      3/27/25 4:30:29 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      3/12/25 5:05:35 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Gilead Sciences Inc.

      144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

      3/10/25 4:02:58 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Gilead Sciences Inc.

      10-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      2/28/25 4:21:03 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 13F-HR filed by Gilead Sciences Inc.

      13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)

      2/13/25 4:14:47 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Gilead Sciences Inc.

      144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/12/25 4:03:19 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

      11/15/24 4:36:27 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling

      11/14/24 11:31:57 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-20) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 10/08/2024. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)

      10/22/24 4:04:28 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-7) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling

      7/18/24 4:46:14 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-5) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215973, Application Classification: Labeling

      7/18/24 4:46:13 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VEKLURY issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug VEKLURY (SUPPL-27) with active ingredient REMDESIVIR has changed to 'Approval' on 06/27/2024. Application Category: NDA, Application Number: 214787, Application Classification: Labeling

      6/28/24 4:37:19 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-19) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 04/24/2024. Application Category: NDA, Application Number: 210251, Application Classification: Efficacy

      4/25/24 10:18:35 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VEMLIDY issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug VEMLIDY (SUPPL-16) with active ingredient TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 208464, Application Classification: Efficacy

      3/27/24 1:12:04 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Gilead Sciences with a new price target

      Cantor Fitzgerald resumed coverage of Gilead Sciences with a rating of Overweight and set a new price target of $125.00

      4/22/25 7:32:53 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Gilead Sciences with a new price target

      Oppenheimer reiterated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $132.00 from $115.00 previously

      3/4/25 8:15:52 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $120.00

      2/18/25 7:09:02 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences upgraded by DZ Bank with a new price target

      DZ Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $108.00

      2/13/25 7:06:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Gilead Sciences from Equal-Weight to Overweight and set a new price target of $113.00 from $87.00 previously

      1/10/25 7:52:44 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities resumed coverage on Gilead Sciences with a new price target

      BofA Securities resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $109.00

      12/10/24 8:28:11 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wolfe Research initiated coverage on Gilead Sciences with a new price target

      Wolfe Research initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $110.00

      11/15/24 7:46:11 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on Gilead Sciences with a new price target

      Citigroup initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $125.00

      11/14/24 7:34:28 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences downgraded by Maxim Group

      Maxim Group downgraded Gilead Sciences from Buy to Hold

      11/8/24 8:43:42 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Gilead Sciences from Market Perform to Outperform and set a new price target of $96.00 from $74.00 previously

      10/21/24 7:41:39 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horning Sandra was granted 1,516 shares, increasing direct ownership by 42% to 5,147 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:26:11 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Manwani Harish covered exercise/tax liability with 296 shares and was granted 1,516 shares, increasing direct ownership by 9% to 14,093 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:18:19 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kramer Kelly A.

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:17:07 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bluestone Jeffrey

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:16:09 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Welters Anthony was granted 1,516 shares, increasing direct ownership by 15% to 11,748 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 6:27:31 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rodriguez Javier was granted 1,516 shares, increasing direct ownership by 14% to 12,218 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 6:25:08 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Love Ted W was granted 1,516 shares, increasing direct ownership by 54% to 4,338 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 6:22:50 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Barton Jacqueline K was granted 1,516 shares, increasing direct ownership by 6% to 26,056 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 6:20:17 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP, Corporate Affairs & GC Telman Deborah H covered exercise/tax liability with 158 shares and converted options into 514 shares, increasing direct ownership by 0.97% to 36,918 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      4/28/25 1:24:48 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Dickinson Andrew D sold $266,000 worth of shares (2,500 units at $106.40), decreasing direct ownership by 1% to 168,174 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      4/16/25 3:22:20 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

      – 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment – Gilead Sciences Inc. (NASDAQ:GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undetectability for one year after end

      5/7/25 2:30:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

      – 60% of Participants with Prior Fibrate or Obeticholic Acid Treatment Achieve Biochemical Response with Livdelzi – – New Evidence Supports Livdelzi Delivers Clinically and Statistically Significant Improvements in Pruritus – Gilead Sciences, Inc. (NASDAQ:GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and statistical

      5/7/25 2:15:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Present at Upcoming Investor Conferences

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time Jefferies Global Healthcare Conference on Wednesday, June 4 at 11:05 AM Eastern Time Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 10 at 11:20 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays wi

      4/29/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

      – New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in people with primary biliary cholangitis (PBC) – – Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus (HDV) – – Presentations in hepatitis B virus (HBV) and hepatitis C virus (HCV) will underscore Gilead's commitment to advancing scientific research and our understanding of viral hepatitis in the real-world setting – Gilead Sciences, Inc. (NASDAQ:GILD) today announced ne

      4/29/25 8:30:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Gilead Sciences Announces First Quarter 2025 Financial Results

      Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our base business grew 4% year-over-year, primarily led by Biktarvy's continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer. With the upcoming June P

      4/24/25 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

      – The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously Untreated PD-L1+ (CPS ≥10) mTNBC – Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresec

      4/21/25 8:30:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa

      4/10/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Center for Disease Analysis Foundation Awards Third Round of Grants for the CDAF Relink Program

      Building on the progress of the first two rounds, the Center for Disease Analysis Foundation (CDAF) Relink program is pleased to announce seven hundred and eighty-two thousand dollars in funding for its third round of grantees. The following six organizations are beneficiaries: Organization Organization Type State Bluestone Health Association Inc. Healthcare Institution WV Carilion Clinic Healthcare Institution VA Cooperman Barnabas Medical Center Healthcare Institution NJ First Choice Primary Care, Inc. Healthcare Institution GA TruReach Inc Healthcare Institution PA University of Kentucky Research

      4/4/25 6:36:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

      – Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – – First and Only Treatment That Achieved Statistically Significant Improvements Across Biochemical Response, Alkaline Phosphatase Normalization, and Pruritus Versus Placebo – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an

      2/20/25 4:30:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

      2/13/24 5:48:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/9/24 6:21:28 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/13/23 3:32:27 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Gilead Sciences Inc.

      SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/13/23 2:49:26 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/9/23 11:19:24 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

      2/11/22 12:22:48 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

      2/10/22 8:11:48 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

      2/16/21 3:46:32 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

      2/16/21 1:27:50 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

      2/10/21 10:57:17 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. Financials

    Live finance-specific insights

    See more
    • Gilead Sciences Announces First Quarter 2025 Financial Results

      Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our base business grew 4% year-over-year, primarily led by Biktarvy's continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer. With the upcoming June P

      4/24/25 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa

      4/10/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

      Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.6% in the company's quarterly cash dividend, beginning in the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. The dividend is payable on March 28, 2025, to stockholders of record at the close of business on March 14, 2025. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

      2/11/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

      Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024 Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2024 Oncology Sales Increased 12% Year-Over-Year to $3.3 billion for Full Year 2024 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "From this foundation of commercial strength, we are planning

      2/11/25 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2024 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a

      1/28/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Announces Third Quarter 2024 Financial Results

      Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance," said Daniel O'Day, Gilead's Chairman and Chief Executive Offic

      11/6/24 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop

      10/9/24 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Announces Second Quarter 2024 Financial Results

      Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its second quarter 2024 results of operations. "Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of our therapies for HIV, Oncology and Liver Disease, including 8% growth for Biktarvy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "One of the key highlights of the quarter was interim data from the Phase 3 PURPOSE 1 trial showing 100% efficacy for lenacapa

      8/8/24 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all pe

      7/25/24 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Announces First Quarter 2024 Financial Results

      Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The acquisition of CymaBay brings us another potent

      4/25/24 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gilead Sciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

      Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in

      12/12/24 5:30:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

      Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa

      6/15/23 4:01:00 PM ET
      $GILD
      $GLPG
      $JNJ
      $LIVN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Gilead Appoints Cindy Perettie Executive Vice President of Kite

      Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005214/en/Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire) Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR (polymerase chain reactio

      5/16/23 4:01:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors

      MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors. Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers. "We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story.  Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa's experience and insights in Long QT Syndrome," said Paul F. Truex, Thryv's

      11/29/22 8:00:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel

      – Brett Pletcher, Executive Vice President, Corporate Affairs and General Counsel to Retire After 17 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Ms. Telman will assume responsibility for Gilead's legal and corporate affairs function, which includes government and policy, and public affairs. Ms. Telman will start in her new role August 1, 2022. She will also become Corporate Secretary of Gilead. Ms. Telman will succeed Brett Plet

      7/12/22 8:30:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing

      – Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Dr. Ma will assume responsibility for Gilead's Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, who is retiring from Gilead after nearly three decades. Dr. Ma brings to her new role more than 25 years of ex

      6/2/22 9:00:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors

      Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold. This press release features multimedia. View the full

      5/16/22 7:30:00 AM ET
      $CRM
      $GILD
      $GOOG
      $HON
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board

      Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company's Advisory Board. "Mr. Allan and Dr. McGraw both have impressive careers in the field of healthcare and biotechnology underscored by tremendously successful exits and we are excited to welcome them to our team," commented Anthony Durkacz, Foun

      4/21/22 8:30:00 AM ET
      $BMY
      $GILD
      $HUGE
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to its Board of Directors

      NEWARK, N.J., June 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE:RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the appointment of three senior biopharmaceutical leaders to its Board of Directors: Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., (NASDAQ GS: MRNA); and Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir Bio. www.rafaelholdings.com (PRNewsfoto/Rafael Holdings, Inc.)" alt="Rafael Holdings holds commercial real estate assets and interests in two clini

      6/14/21 4:45:00 PM ET
      $GILD
      $RFL
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance